Meeting
2023 ASCO Genitourinary Cancers Symposium
Real-world combination therapy patterns in patients receiving leuprolide or relugolix for androgen deprivation therapy in 2021 (The REAL-ADT COMBO Study): Analysis from a US EMR database.
Authors
Rana R. McKay
Moores Cancer Center, University of California San Diego, La Jolla, CA
Rana R. McKay , Raj Gandhi , Eric Yang , Janis Pruett , Esmond Nwokeji , Mark Fallick
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 74)
DOI
10.1200/JCO.2023.41.6_suppl.74
Abstract #
74
Poster Bd #
C4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2023 ASCO Genitourinary Cancers Symposium
A multi-center, prospective, observational study of patients with prostate cancer being treated with relugolix: OPTYX.
First Author: Daniel Eidelberg Spratt
Poster
2024 ASCO Genitourinary Cancers Symposium
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy (iADT) with relugolix.
First Author: Patrick Campbell
Poster
2024 ASCO Genitourinary Cancers Symposium
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.
First Author: Sagar A. Patel